Log in

Relevant bibliographies by topics / Drug delivery systems / Journal articles

Journal articles on the topic 'Drug delivery systems'

To see the other types of publications on this topic, follow the link: Drug delivery systems.

Author: Grafiati

Published: 4 June 2021

Last updated: 30 July 2024

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Drug delivery systems.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Sharma, Abhimanyu Rai, Binu Raina, Prabhjot Singh Bajwa, Pankaj Sharma, Anurag Bhargava, and Shailesh Sharma. "Chronotherapeutic drug delivery systems." Asian Pacific Journal of Health Sciences 5, no. 2 (June 2018): 189–95. http://dx.doi.org/10.21276/apjhs.2018.5.2.36.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Langer, Robert. "Drug Delivery Systems." MRS Bulletin 16, no. 9 (September 1991): 47–49. http://dx.doi.org/10.1557/s0883769400056050.

Full text

Abstract:

For many years, drug delivery systems were composed of simple pills, eyedrops, ointments, or intravenous solutions. Recently, materials have begun to play a major role in improving drug delivery. Drugs are now chemically attached to polymers, entrapped in small vesicles that are injected into the bloodstream, or put in pumps or polymeric materials that are placed in the body. These new materials-based systems are beginning to change the way drugs can be administered and, in so doing, have improved human health. This article provides a brief review of the major classes of drug delivery systems; a recent paper discusses these issues in detail.Chemically attaching a drug to a polymer may alter such properties as its distribution in the body, rate of appearance in certain tissues, solubility, or antigenicity. For example, drugs have been linked to soluble macromolecules such as proteins, polysaccharides, or synthetic polymers via degradable linkages. This alters the drug's size and other properties, resulting in a different bodily drug distribution pattern. One example involves coupling the antitumor agent neocarzinostatin to styrene-maleic acid copolymers. When this complex was injected intra-arterially in patients with liver cancer, tumor size decreased significantly. In animals, the antitumor agent, doxorubicin, bound to N(2-hydroxypropyl) methacrylamide copolymers reduced toxicity. The plasma half-life and the drug levels in the tumor increased while the concentrations in the rest of the body decreased.

APA, Harvard, Vancouver, ISO, and other styles

3

Berillo, Dmitriy, Adilkhan Yeskendir, Zharylkasyn Zharkinbekov, Kamila Raziyeva, and Arman Saparov. "Peptide-Based Drug Delivery Systems." Medicina 57, no. 11 (November 5, 2021): 1209. http://dx.doi.org/10.3390/medicina57111209.

Full text

Abstract:

Peptide-based drug delivery systems have many advantages when compared to synthetic systems in that they have better biocompatibility, biochemical and biophysical properties, lack of toxicity, controlled molecular weight via solid phase synthesis and purification. Lysosomes, solid lipid nanoparticles, dendrimers, polymeric micelles can be applied by intravenous administration, however they are of artificial nature and thus may induce side effects and possess lack of ability to penetrate the blood-brain barrier. An analysis of nontoxic drug delivery systems and an establishment of prospective trends in the development of drug delivery systems was needed. This review paper summarizes data, mainly from the past 5 years, devoted to the use of peptide-based carriers for delivery of various toxic drugs, mostly anticancer or drugs with limiting bioavailability. Peptide-based drug delivery platforms are utilized as peptide–drug conjugates, injectable biodegradable particles and depots for delivering small molecule pharmaceutical substances (500 Da) and therapeutic proteins. Controlled drug delivery systems that can effectively deliver anticancer and peptide-based drugs leading to accelerated recovery without significant side effects are discussed. Moreover, cell penetrating peptides and their molecular mechanisms as targeting peptides, as well as stimuli responsive (enzyme-responsive and pH-responsive) peptides and peptide-based self-assembly scaffolds are also reviewed.

APA, Harvard, Vancouver, ISO, and other styles

4

K Purushotham and K Anie Vijetha. "A review on transdermal drug delivery system." GSC Biological and Pharmaceutical Sciences 22, no. 2 (February 28, 2023): 245–55. http://dx.doi.org/10.30574/gscbps.2023.22.2.0053.

Full text

Abstract:

In order to produce systemic effects, transdermal drug delivery systems (TDDS), commonly referred to as "patches," are dosage forms that are intended to spread a therapeutically active amount of medicine across the skin of a patient. Drugs that are applied topically are delivered using transdermal drug delivery devices. These are pharmaceutical preparations of varying sizes, containing one or more active ingredients, intended to be applied to the unbroken skin in order to deliver the active ingredient after passing through the skin barriers, and these avoid first pass metabolism. Today about 74% of drugs are taken orally and are not found effective as desired. To improve efficacy transdermal drug delivery system was emerged. In TDDS the drug easily penetrates into the skin and easily reaches the target site. To get around the problems with medicine delivery via oral route, transdermal drug delivery systems were developed. These systems have been utilized as secure and reliable drug delivery systems since 1981.

APA, Harvard, Vancouver, ISO, and other styles

5

Chavhan, Sarin A., Sushilkumar A. Shinde, Sandip B. Sapkal, and Vinayak N. Shrikhande. "Herbal excipients in Novel Drug Delivery Systems." International Journal of Research and Development in Pharmacy & Life Sciences 6, no. 3 (April 2017): 2597–605. http://dx.doi.org/10.21276/ijrdpl.2278-0238.2017.6(3).2597-2605.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Ranade, Vasant V. "Drug Delivery Systems 5A. Oral Drug Delivery." Journal of Clinical Pharmacology 31, no. 1 (January 1991): 2–16. http://dx.doi.org/10.1002/j.1552-4604.1991.tb01881.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Ranade, Vasant V. "Drug Delivery Systems. 6. Transdermal Drug Delivery." Journal of Clinical Pharmacology 31, no. 5 (May 1991): 401–18. http://dx.doi.org/10.1002/j.1552-4604.1991.tb01895.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Ranade, Vasant V. "Drug Delivery Systems 5B. Oral Drug Delivery." Journal of Clinical Pharmacology 31, no. 2 (February 1991): 98–115. http://dx.doi.org/10.1002/j.1552-4604.1991.tb03693.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

Mali, Audumbar Digambar, Ritesh Bathe, and Manojkumar Patil. "An updated review on transdermal drug delivery systems." International Journal of Advances in Scientific Research 1, no. 6 (July 30, 2015): 244. http://dx.doi.org/10.7439/ijasr.v1i6.2243.

Full text

Abstract:

Transdermal drug delivery systems (TDDS), also known as patches, are dosage forms designed to deliver a therapeutically effective amount of drug across a patients skin. In order to deliver therapeutic agents through the human skin for systemic effects, the comprehensive morphological, biophysical and physicochemical properties of the skin are to be considered. Transdermal delivery provides a leading edge over injectables and oral routes by increasing patient compliance and avoiding first pass metabolism respectively. Transdermal delivery not only provides controlled, constant administration of the drug, but also allows continuous input of drugs with short biological half-lives and eliminates pulsed entry into systemic circulation, which often causes undesirable side effects. The TDDS review articles provide valuable information regarding the transdermal drug delivery systems and its evaluation process details as a ready reference for the research scientist who is involved in TDDS. With the advancement in technology Pharma industries have trendified all its resources. Earlier we use convectional dosage form but now we use novel drug delivery system. One of greatest innovation of novel drug delivery is transdermal patch. The advantage of transdermal drug delivery system is that it is painless technique of administration of drugs.

APA, Harvard, Vancouver, ISO, and other styles

10

Polack, Alan, and Michael Roberts. "Drug delivery systems." Medical Journal of Australia 144, no. 6 (March 1986): 311–14. http://dx.doi.org/10.5694/j.1326-5377.1986.tb128383.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

11

Davis, S. S. "Drug delivery systems." Interdisciplinary Science Reviews 25, no. 3 (March 2000): 175–83. http://dx.doi.org/10.1179/030801800679206.

Full text

APA, Harvard, Vancouver, ISO, and other styles

12

Roberts, M. S. "Drug‐delivery systems." Medical Journal of Australia 150, no. 9 (May 1989): 522. http://dx.doi.org/10.5694/j.1326-5377.1989.tb136612.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

13

Erdine, Serdar, and Jose De Andres. "Drug Delivery Systems." Pain Practice 6, no. 1 (March 2006): 51–57. http://dx.doi.org/10.1111/j.1533-2500.2006.00059.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

14

Robinson, Dennis H., and John W. Mauger. "Drug delivery systems." American Journal of Health-System Pharmacy 48, no. 10_suppl (October 1, 1991): S14—S23. http://dx.doi.org/10.1093/ajhp/48.10_suppl_1.s14.

Full text

APA, Harvard, Vancouver, ISO, and other styles

15

Somberg, J. "Drug Delivery Systems." American Journal of Therapeutics 11, no. 2 (March 2004): 154. http://dx.doi.org/10.1097/00045391-200403000-00011.

Full text

APA, Harvard, Vancouver, ISO, and other styles

16

NIKANDER, KURT. "Drug Delivery Systems." Journal of Aerosol Medicine 7, s1 (January 1994): S—19—S—24. http://dx.doi.org/10.1089/jam.1994.7.suppl_1.s-19.

Full text

APA, Harvard, Vancouver, ISO, and other styles

17

Pazdernik, Thomas L. "DRUG DELIVERY SYSTEMS." Shock 30, no. 3 (September 2008): 339. http://dx.doi.org/10.1097/01.shk.0000286298.94327.b3.

Full text

APA, Harvard, Vancouver, ISO, and other styles

18

Branno-Peppas, Lisa. "Drug delivery systems." Biomaterials 18, no. 5 (March 1997): 449. http://dx.doi.org/10.1016/s0142-9612(97)85703-1.

Full text

APA, Harvard, Vancouver, ISO, and other styles

19

Mathiowitz, Edith. "Drug Delivery Systems." Toxicologic Pathology 36, no. 1 (January 2008): 16–20. http://dx.doi.org/10.1177/0192623307311411.

Full text

APA, Harvard, Vancouver, ISO, and other styles

20

Pandey, Parijat, Manisha Saini, and Neeta . "Mucoadhesive drug delivery system: an overview." Pharmaceutical and Biological Evaluations 4, no. 4 (August 1, 2017): 183. http://dx.doi.org/10.26510/2394-0859.pbe.2017.29.

Full text

Abstract:

The major objective of any dosage form is to deliver an optimum therapeutic amount of active agent to the proper site in the body to attain constant & maintenance of the desired drug concentration. Mucoadhesive drug delivery systems are effective delivery systems with various advantages as compared to other oral controlled release dosage forms in terms of drug delivery at specific sites with prolonged retention time of drugs at target sites. The main advantage of these systems includes avoiding first pass metabolism of the drugs and hence availability of high drug concentration at target site. Oral mucoadhesive systems have potential ability for controlled and extended release profile so as to get better performance and patient compliance. The present manuscript briefly reviews the benefits of mucoadhesive drug delivery systems, mechanisms involved in mucoadhesion, different factors affecting mucoadhesive drug delivery systems.

APA, Harvard, Vancouver, ISO, and other styles

21

Demchuk, Zoriana, Mariya Savka, Andriy Voronov, Olga Budishevska, Volodymyr Donchak, and Stanislav Voronov. "Amphiphilic Polymers Containing Cholesterol for Drug Delivery Systems." Chemistry & Chemical Technology 10, no. 4s (December 25, 2016): 561–70. http://dx.doi.org/10.23939/chcht10.04si.561.

Full text

Abstract:

The interaction of binary copolymers poly(maleic anhydride-co-poly(ethylene glycol) methyl ether methacrylate) with cholesterol results in formation of cholesterol containing polymers, which contain from 4.6 to 46.0 mol % monocholesteryl maleic links. Their structure was confirmed using functional analysis and IR spectroscopy. Acidic and anhydride links of these copolymers form polymeric salts if react with alkali. These salts are surfactants which in aqueous medium form a hierarchy micelles and micellar aggregates depending on the copolymer concentration. Using conductometry it was found that preferably monomolecular micelles are formed in dilute solutions, and micellar aggregates begin to form at higher concentrations. In aqueous media polymeric salts are able to solubilize such lipophilic substances as Sudan III dye and anticancer drug curcumin. Efficiency of solubilization towards Sudan III grows if the content of monocholesteryl maleic fragment in surfactant increases.

APA, Harvard, Vancouver, ISO, and other styles

22

Batur, Eslim, Samet Özdemir, Meltem Ezgi Durgun, and Yıldız Özsoy. "Vesicular Drug Delivery Systems: Promising Approaches in Ocular Drug Delivery." Pharmaceuticals 17, no. 4 (April 16, 2024): 511. http://dx.doi.org/10.3390/ph17040511.

Full text

Abstract:

Ocular drug delivery poses unique challenges due to the complex anatomical and physiological barriers of the eye. Conventional dosage forms often fail to achieve optimal therapeutic outcomes due to poor bioavailability, short retention time, and off-target effects. In recent years, vesicular drug delivery systems have emerged as promising solutions to address these challenges. Vesicular systems, such as liposome, niosome, ethosome, transfersome, and others (bilosome, transethosome, cubosome, proniosome, chitosome, terpesome, phytosome, discome, and spanlastics), offer several advantages for ocular drug delivery. These include improved drug bioavailability, prolonged retention time on the ocular surface, reduced systemic side effects, and protection of drugs from enzymatic degradation and dilution by tears. Moreover, vesicular formulations can be engineered for targeted delivery to specific ocular tissues or cells, enhancing therapeutic efficacy while minimizing off-target effects. They also enable the encapsulation of a wide range of drug molecules, including hydrophilic, hydrophobic, and macromolecular drugs, and the possibility of combination therapy by facilitating the co-delivery of multiple drugs. This review examines vesicular drug delivery systems, their advantages over conventional drug delivery systems, production techniques, and their applications in management of ocular diseases.

APA, Harvard, Vancouver, ISO, and other styles

23

Sudhakar, Dr Uma, K. Ruth Gethsie, H. Priyanka, and SS Fathima Zinneerah. "Local drug delivery drugs and systems." International Journal of Applied Dental Sciences 6, no. 4 (October 1, 2020): 70–73. http://dx.doi.org/10.22271/oral.2020.v6.i4b.1047.

Full text

APA, Harvard, Vancouver, ISO, and other styles

24

Davies, M. "Polymeric Drugs and Drug Delivery Systems." Biomaterials 14, no. 3 (January 1993): 239. http://dx.doi.org/10.1016/0142-9612(93)90033-x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

25

Martini, Alessandro, and Cristina Ciocca. "Drug delivery systems for cancer drugs." Expert Opinion on Therapeutic Patents 13, no. 12 (December 2003): 1801–7. http://dx.doi.org/10.1517/13543776.13.12.1801.

Full text

APA, Harvard, Vancouver, ISO, and other styles

26

Kennedy, John F., and Giampiero Pagliuca. "Polymeric Drugs and Drug Delivery Systems." Carbohydrate Polymers 18, no. 4 (January 1992): 311–12. http://dx.doi.org/10.1016/0144-8617(92)90098-b.

Full text

APA, Harvard, Vancouver, ISO, and other styles

27

Ranade, Vasant V. "Drug Delivery Systems 4. Implants in Drug Delivery." Journal of Clinical Pharmacology 30, no. 10 (October 1990): 871–89. http://dx.doi.org/10.1002/j.1552-4604.1990.tb03566.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

28

Shrestha, Hina, Rajni Bala, and Sandeep Arora. "Lipid-Based Drug Delivery Systems." Journal of Pharmaceutics 2014 (May 19, 2014): 1–10. http://dx.doi.org/10.1155/2014/801820.

Full text

Abstract:

The principle objective of formulation of lipid-based drugs is to enhance their bioavailability. The use of lipids in drug delivery is no more a new trend now but is still the promising concept. Lipid-based drug delivery systems (LBDDS) are one of the emerging technologies designed to address challenges like the solubility and bioavailability of poorly water-soluble drugs. Lipid-based formulations can be tailored to meet a wide range of product requirements dictated by disease indication, route of administration, cost consideration, product stability, toxicity, and efficacy. These formulations are also a commercially viable strategy to formulate pharmaceuticals, for topical, oral, pulmonary, or parenteral delivery. In addition, lipid-based formulations have been shown to reduce the toxicity of various drugs by changing the biodistribution of the drug away from sensitive organs. However, the number of applications for lipid-based formulations has expanded as the nature and type of active drugs under investigation have become more varied. This paper mainly focuses on novel lipid-based formulations, namely, emulsions, vesicular systems, and lipid particulate systems and their subcategories as well as on their prominent applications in pharmaceutical drug delivery.

APA, Harvard, Vancouver, ISO, and other styles

29

Ma, Zhiyuan, Baicheng Li, Jie Peng, and Dan Gao. "Recent Development of Drug Delivery Systems through Microfluidics: From Synthesis to Evaluation." Pharmaceutics 14, no. 2 (February 17, 2022): 434. http://dx.doi.org/10.3390/pharmaceutics14020434.

Full text

Abstract:

Conventional drug administration usually faces the problems of degradation and rapid excretion when crossing many biological barriers, leading to only a small amount of drugs arriving at pathological sites. Therapeutic drugs delivered by drug delivery systems to the target sites in a controlled manner greatly enhance drug efficacy, bioavailability, and pharmacokinetics with minimal side effects. Due to the distinct advantages of microfluidic techniques, microfluidic setups provide a powerful tool for controlled synthesis of drug delivery systems, precisely controlled drug release, and real-time observation of drug delivery to the desired location at the desired rate. In this review, we present an overview of recent advances in the preparation of nano drug delivery systems and carrier-free drug delivery microfluidic systems, as well as the construction of in vitro models on-a-chip for drug efficiency evaluation of drug delivery systems. We firstly introduce the synthesis of nano drug delivery systems, including liposomes, polymers, and inorganic compounds, followed by detailed descriptions of the carrier-free drug delivery system, including micro-reservoir and microneedle drug delivery systems. Finally, we discuss in vitro models developed on microfluidic devices for the evaluation of drug delivery systems, such as the blood–brain barrier model, vascular model, small intestine model, and so on. The opportunities and challenges of the applications of microfluidic platforms in drug delivery systems, as well as their clinical applications, are also discussed.

APA, Harvard, Vancouver, ISO, and other styles

30

Parmar, Ramesh D., Rajesh K. Parikh, G. Vidyasagar, Dhaval V. Patel, Chirag J. Patel, and Biraju D. Patel. "Pulsatile Drug Delivery Systems: An Overview." International Journal of Pharmaceutical Sciences and Nanotechnology 2, no. 3 (November 30, 2009): 605–14. http://dx.doi.org/10.37285/ijpsn.2009.2.3.3.

Full text

Abstract:

Pulsatile Drug Delivery Systems are gaining a lot of interest as they deliver the drug at the right place at the right time and in the right amount, thus providing spatial and temporal delivery and increasing patient compliance. These systems are designed according to the circadian rhythm of the body. The principle rationale for the use of pulsatile release of the drugs is where a constant drug release is not desired. A pulse has to be designed in such a way that a complete and rapid drug release is achieved after the lag time. Various systems like capsular systems, osmotic systems, single- and multiple-unit systems based on the use of soluble or erodible polymer coating and use of rupturable membranes have been dealt with in the article. It summarizes the latest technological developments, formulation parameters, and release profiles of these systems. These systems are beneficial for the drugs having chronopharmacological behavior where night time dosing is required, such as anti-arhythmic and anti-asthmatic.

APA, Harvard, Vancouver, ISO, and other styles

31

Nadigoti, Jagadeesh, and Shayeda. "Floating Drug Delivery Systems." International Journal of Pharmaceutical Sciences and Nanotechnology 2, no. 3 (November 30, 2009): 595–604. http://dx.doi.org/10.37285/ijpsn.2009.2.3.2.

Full text

Abstract:

Management of illness through medication is entering a new era in which growing number of novel drug delivery systems are being employed and are available for therapeutic use. Oral sustained release gastro-retentive dosage forms (GRDFs) offer many advantages for drugs with absorption from upper parts of gastrointestinal tract and for those acting locally in the stomach, improving the bioavailability of the medication. Floating Drug Delivery Systems (FDDS) is one amongst the GRDFs used to achieve prolonged gastric residence time. Multiple unit FDDS avoid “all-or-nothing” gastric emptying nature of single unit systems. Apart from the background, formulation aspects and evaluation of FDDS, recent developments are also covered in this review.

APA, Harvard, Vancouver, ISO, and other styles

32

Chawra, Himmat Singh, Y. S. Tanwar, Ritu M. Gilhotra, and S. K. Singh. "Gastroretentive drug delivery systems a potential approach for antihypertensive drugs: An updated review." Asian Pacific Journal of Health Sciences 5, no. 2 (June 2018): 217–23. http://dx.doi.org/10.21276/apjhs.2018.5.2.40.

Full text

APA, Harvard, Vancouver, ISO, and other styles

33

RK, Gunda. "Transdermal Drug Delivery System: An Emphasis on Transdermal Patches." Pharmaceutical Drug Regulatory Affairs Journal 6, no. 1 (June 29, 2023): 1–5. http://dx.doi.org/10.23880/pdraj-16000147.

Full text

Abstract:

Transdermal drug delivery system was presented to overcome the difficulties of drug delivery especially oral route. A transdermal patch is a medicated adhesive patch that is placed on the skin to deliver a specific dose of medication through the skin and into the bloodstream. It promotes healing to an injured area of the body. An advantage of a transdermal drug delivery route over other types of delivery system such as oral, topical, i.v., i.m., etc. is that the patch provides a controlled release of the medication into the patient, usually through either a porous membrane covering a reservoir of medication or through body heat melting thin layers of medication embedded in the adhesive. The main disadvantage to transdermal delivery systems stems from the fact that the skin is a very effective barrier, as a result, only medications whose molecules are small can easily penetrate the skin, so it can be delivered by this method. This review article describes the overall introduction of transdermal patches including type of transdermal patches, method of preparation of transdermal patches and factor affecting etc.

APA, Harvard, Vancouver, ISO, and other styles

34

Wang, Ye, Yongsheng Wei, Hui Liao, Hongwei Fu, Xiaobin Yang, Qi Xiang, and Shu Zhang. "Plant Exosome-like Nanoparticles as Biological Shuttles for Transdermal Drug Delivery." Bioengineering 10, no. 1 (January 12, 2023): 104. http://dx.doi.org/10.3390/bioengineering10010104.

Full text

Abstract:

Exosomes act as emerging transdermal drug delivery vehicles with high deformability and excellent permeability, which can be used to deliver various small-molecule drugs and macromolecular drugs and increase the transdermal and dermal retention of drugs, improving the local efficacy and drug delivery compliance. At present, there are many studies on the use of plant exosome-like nanoparticles (PELNVs) as drug carriers. In this review, the source, extraction, isolation, and chemical composition of plant exosomes are reviewed, and the research progress on PELNVs as drug delivery systems in transdermal drug delivery systems in recent years has elucidated the broad application prospect of PELNVs.

APA, Harvard, Vancouver, ISO, and other styles

35

Ng, Jaryl Chen Koon, Daniel Wee Yee Toong, Valerie Ow, Su Yin Chaw, Hanwei Toh, Philip En Hou Wong, Subbu Venkatraman, et al. "Progress in drug-delivery systems in cardiovascular applications: stents, balloons and nanoencapsulation." Nanomedicine 17, no. 5 (February 2022): 325–47. http://dx.doi.org/10.2217/nnm-2021-0288.

Full text

Abstract:

Drug-delivery systems in cardiovascular applications regularly include the use of drug-eluting stents and drug-coated balloons to ensure sufficient drug transfer and efficacy in the treatment of cardiovascular diseases. In addition to the delivery of antiproliferative drugs, the use of growth factors, genetic materials, hormones and signaling molecules has led to the development of different nanoencapsulation techniques for targeted drug delivery. The review will cover drug delivery and coating mechanisms in current drug-eluting stents and drug-coated balloons, novel innovations in drug-eluting stent technologies and drug encapsulation in nanocarriers for delivery in vascular diseases. Newer technologies and advances in nanoencapsulation techniques, such as the use of liposomes, nanogels and layer-by-layer coating to deliver therapeutics in the cardiovascular space, will be highlighted.

APA, Harvard, Vancouver, ISO, and other styles

36

Rohini U, Sante, Ajay Fugate, Priyanka D. Yelkote, Madhuri M. Phulari, Sneha R. Patil, Punam V. Ritthe, and Imran Shaikh I. "A Review on Transdermal Drug Delivery System." Asian Journal of Pharmaceutical Research and Development 12, no. 2 (April 15, 2024): 77–86. http://dx.doi.org/10.22270/ajprd.v12i2.1365.

Full text

Abstract:

Transdermal patches are designed to deliver drugs across the skin membrane without causing pain. This method of drug delivery, known as transdermal delivery, was first used in 1981 when Ciba-Geigy smarketed Transdermal V (now marketed as Transderm Scop) to prevent nausea and vomiting associated with motion sickness. Transdermal patches are pharmaceutical preparations of varying sizes, containing one or more active ingredients, which are applied to unbroken skin to deliver the active ingredient after passing through the skin barriers, thus avoiding first-pass metabolism. Today, about 74% of drugs are taken orally and often prove ineffective. To improve drug efficacy, transdermal drug delivery systems have emerged. The main objective of these systems is to deliver drugs into systemic circulation through the skin at a predetermined rate with minimal inter- and intra-patient variations.

APA, Harvard, Vancouver, ISO, and other styles

37

Karmakar, Shaswata, Shashikiran Shanmugasundaram, and Baishakhi Modak. "Oleogel-based drug delivery for the treatment of periodontitis: current strategies and future perspectives." F1000Research 12 (September 27, 2023): 1228. http://dx.doi.org/10.12688/f1000research.140173.1.

Full text

Abstract:

Periodontitis is the chronic inflammation of tooth-supporting tissues that leads to loss of tooth support if untreated. Conventional therapy for periodontitis (mechanical removal of microbial biofilm and oral hygiene enforcement) is augmented by anti-microbial and anti-inflammatory drugs. These drugs are frequently delivered locally into the periodontal pocket for maximum efficiency and minimum adverse effects. The potential of oleogels for periodontal drug delivery has been discussed and further, the future scope of oleogel-based drug delivery systems in dentistry. An oleogel-based local drug delivery system offers several advantages over other systems. Superior mechanical properties (firmness and compressibility), muco-adhesion, shear thinning, thixotropy, controlled drug release and the ability to incorporate water-insoluble drugs clearly distinguish and highlight the potential of oleogels as periodontal local drug delivery systems. Bigels can combine the qualities of both hydrogels and oleogels to provide a more promising option for drug delivery. However, there is limited evidence concerning oleogels as local drug delivery agents in periodontics. Further studies are needed to discern the clinical efficacy of oleogel-based drug delivery systems.

APA, Harvard, Vancouver, ISO, and other styles

38

Bussemer, Till, Ina Otto, and Roland Bodmeier. "Pulsatile Drug-Delivery Systems." Critical Reviews in Therapeutic Drug Carrier Systems 18, no. 5 (2001): 26. http://dx.doi.org/10.1615/critrevtherdrugcarriersyst.v18.i5.10.

Full text

APA, Harvard, Vancouver, ISO, and other styles

39

Lalwani, Anita, and DD Santani. "Pulsatile drug delivery systems." Indian Journal of Pharmaceutical Sciences 69, no. 4 (2007): 489. http://dx.doi.org/10.4103/0250-474x.36932.

Full text

APA, Harvard, Vancouver, ISO, and other styles

40

He, Wentian. "Pegylated Drug Delivery Systems." Journal of Drug Delivery and Therapeutics 9, no. 2 (March 15, 2019): 406–8. http://dx.doi.org/10.22270/jddt.v9i2.2422.

Full text

APA, Harvard, Vancouver, ISO, and other styles

41

Banerjee, Partha S., and Joseph R. Robinson. "Novel Drug Delivery Systems." Clinical Pharmacokinetics 20, no. 1 (January 1991): 1–14. http://dx.doi.org/10.2165/00003088-199120010-00001.

Full text

APA, Harvard, Vancouver, ISO, and other styles

42

Donnelly, RyanF, Rahamatullah Shaikh, ThakurRaghu Raj Singh, MartinJames Garland, and ADavid Woolfson. "Mucoadhesive drug delivery systems." Journal of Pharmacy and Bioallied Sciences 3, no. 1 (2011): 89. http://dx.doi.org/10.4103/0975-7406.76478.

Full text

APA, Harvard, Vancouver, ISO, and other styles

43

Carvalho, Flávia Chiva, Marcos Luciano Bruschi, Raul Cesar Evangelista, and Maria Palmira Daflon Gremião. "Mucoadhesive drug delivery systems." Brazilian Journal of Pharmaceutical Sciences 46, no. 1 (March 2010): 1–17. http://dx.doi.org/10.1590/s1984-82502010000100002.

Full text

Abstract:

Drug actions can be improved by developing new drug delivery systems, such as the mucoadhesive system. These systems remain in close contact with the absorption tissue, the mucous membrane, releasing the drug at the action site leading to a bioavailability increase and both local and systemic effects. Mucoadhesion is currently explained by six theories: electronic, adsorption, wettability, diffusion, fracture and mechanical. Several in vitro and in vivo methodologies are proposed for studying its mechanisms. However, mucoadhesion is not yet well understood. The aim of this study was to review the mechanisms and theories involved in mucoadhesion, as well as to describe the most-used methodologies and polymers in mucoadhesive drug delivery systems.

APA, Harvard, Vancouver, ISO, and other styles

44

Ahuja, Alka, Roop K. Khar, and Javed Ali. "Mucoadhesive Drug Delivery Systems." Drug Development and Industrial Pharmacy 23, no. 5 (January 1997): 489–515. http://dx.doi.org/10.3109/03639049709148498.

Full text

APA, Harvard, Vancouver, ISO, and other styles

45

Senior, Judy H. "Nanoparticulate Drug Delivery Systems." Drug Development and Industrial Pharmacy 34, no. 1 (January 2008): 116. http://dx.doi.org/10.1080/03639040701877119.

Full text

APA, Harvard, Vancouver, ISO, and other styles

46

Murphy, Terence. "Alternative drug delivery systems." American Journal of Hospice and Palliative Medicine® 8, no. 6 (November 1991): 36–42. http://dx.doi.org/10.1177/104990919100800606.

Full text

APA, Harvard, Vancouver, ISO, and other styles

47

Chien, Yie W., and Jue-Chen Liu. "Transdermal Drug Delivery Systems." Journal of Biomaterials Applications 1, no. 2 (April 1986): 183–206. http://dx.doi.org/10.1177/088532828600100202.

Full text

APA, Harvard, Vancouver, ISO, and other styles

48

Jiménez-castellanos, Ma Rosa, Hussein Zia, and C. T. Rhodes. "Mucoadhesive Drug Delivery Systems." Drug Development and Industrial Pharmacy 19, no. 1-2 (January 1993): 143–94. http://dx.doi.org/10.3109/03639049309038765.

Full text

APA, Harvard, Vancouver, ISO, and other styles

49

Chidambaram, N., and A. K. Srivatsava. "Buccal Drug Delivery Systems." Drug Development and Industrial Pharmacy 21, no. 9 (January 1995): 1009–36. http://dx.doi.org/10.3109/03639049509069802.

Full text

APA, Harvard, Vancouver, ISO, and other styles

50

&NA;. "Respiratory drug delivery systems." Inpharma Weekly &NA;, no. 825 (February 1992): 12–13. http://dx.doi.org/10.2165/00128413-199208250-00021.

Full text

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!